Advanced non-small cell lung cancer in elderly patients: A review

Table 2 Retrospective data analyses of elderly patients enrolled in phase III trials with cisplatin- or carboplatin-based chemotherapy

Ref.	Treatment	Age (yr)	No. of patients	RR	MST (mo)	P value
Nguyen et al[27]	CDDP + GEM	≥ 70	53	15%	7.7	NS
		< 70	207	29%	9.4
Kelly et al[28]	CBDCA + TAX	≥ 70	117	NR	6.9	0.06
	CDDP + VNR	< 70	491	NR	8.6
Langer et al[26]	CDDP + VP-16	≥ 70	86	23.3%	8.5	NS
	CDDP + TAX	< 70	488	21.5%	9.1
Rocha Lima et al[32]	CDDP + VBL	≥ 70	31	16%	5.7	NS
		< 70	222	31%	8.0
Hensing et al[33]	CBDCA + TAX	≥ 70	67	27%	7.1	NS
		< 70	163	20%	7.8
Belani et al[30]	CDDP + TXT	≥ 65	149	NR	12.6	NS
		All ages	408	32%	11.3
	CDDP + VNR	≥ 65	134	NR	9.9	NS
		All ages	404	25%	10.1
	CBDCA + TXT	≥ 65	118	NR	9.0	NS
		All ages	406	24%	9.4
Belani et al[30]	CBDCA + TAXw	≥ 70	70	25.7%	9.2	NR
		< 70	147	28.6%	9.6
	CBDCA + TAX	≥ 70	63	19%	7.7	NR
		< 70	151	19.2%	11.4
Lilenbaum et al[29]	CBDCA + TAX	≥ 70	77	36%	8.0	NS
		< 70	207	30%	8.5

CDDP: Cisplatin; CBDCA: Carboplatin; TAX: Paclitaxel; TXT: Docetaxel; VNR: Vinorelbine; GEM: Gemcitabine; VBL: Vinblastine; VP-16: Etoposide; RR: Response rate; MST: Median survival time; S: Survival; NR: Not reported; NS: Not significant.